BioNews Services has a proven track record for playing a key role in helping pharmaceutical companies and their media partners successfully launch newly-approved drugs in rare disease markets, reaching out and engaging patients and caregivers in a meaningful way that drives key value and performance indicators. Time and time again, our approach has shown to be incredibly value-driven, producing substantial quantities of referrals to drug product sites that engage and convert around KPIs well above media agencies’ traditional benchmarks for success.

With 96% of BioNews readers indicating that they trust the accuracy, independence, and authority of our rare disease content, rare disease drug launches benefit from the trust, authority, and connection that our platforms enjoy among our readers. This high level of engagement, combined with 100% alignment between our content and needed demographics for product launches, historically leads to patient acquisition and after-action value add costs 70 to 80% lower than our competitors.

BioNews has played a key role in recent drug

Multiple Sclerosis

Spinal Muscular Atrophy

Pulmonary Fibrosis

Cystic Fibrosis

Amyotrophic Lateral Sclerosis

Pulmonary Fibrosis

Parkinson’s Disease

The unique user data on many of our rare disease sites indicate that we reach 100% of rare disease patient populations.
Our user communities are highly engaged, with a majority visiting the site 3-5 times per week.
Research into our user base reveals that 90%+ of our readers identify as patients or caregivers.
96% of readers indicate that they trust the accuracy, independence, and authority our rare disease content.
Our rare disease platforms are multi-channel, multi-content ecospheres that engage rare disease communities via e-mail, web content, and social media.


For more information on our marketing services, contact [email protected], or fill out the form below.